BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9289638)

  • 1. Risk of breast cancer in carriers of BRCA gene mutations.
    Birkmeyer JD; Welch HG
    N Engl J Med; 1997 Sep; 337(11):787-8; author reply 789. PubMed ID: 9289638
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of breast cancer in carriers of BRCA gene mutations.
    Orlando R
    N Engl J Med; 1997 Sep; 337(11):787; author reply 789. PubMed ID: 9289637
    [No Abstract]   [Full Text] [Related]  

  • 3. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
    Schrag D; Kuntz KM; Garber JE; Weeks JC
    N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of breast cancer in carriers of BRCA gene mutations.
    Whittemore AS
    N Engl J Med; 1997 Sep; 337(11):788-9. PubMed ID: 9289641
    [No Abstract]   [Full Text] [Related]  

  • 6. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR
    J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
    Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
    Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA genes--bookmaking, fortunetelling, and medical care.
    Healy B
    N Engl J Med; 1997 May; 336(20):1448-9. PubMed ID: 9145684
    [No Abstract]   [Full Text] [Related]  

  • 11. The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations.
    Grann VR; Jacobson JS; Sundararajan V; Albert SM; Troxel AB; Neugut AI
    Cancer J Sci Am; 1999; 5(5):283-92. PubMed ID: 10526669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventive gynecologic surgery for BRCA1/2 carriers--information for decision-making.
    Quillin JM; Boardman CH; Bodurtha J; Smith T
    Gynecol Oncol; 2001 Oct; 83(1):168-70. PubMed ID: 11585435
    [No Abstract]   [Full Text] [Related]  

  • 13. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance.
    Agnantis NJ; Paraskevaidis E; Roukos D
    Ann Surg Oncol; 2004 Dec; 11(12):1030-4. PubMed ID: 15545500
    [No Abstract]   [Full Text] [Related]  

  • 14. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
    Schrag D; Kuntz KM; Garber JE; Weeks JC
    JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex decision-making for BRCA1/2 carriers.
    Matloff ET
    Cancer J Sci Am; 1999; 5(5):266-8. PubMed ID: 10526666
    [No Abstract]   [Full Text] [Related]  

  • 17. Breast & ovarian cancer. Issues in risk assessment.
    Caro SW
    Adv Nurse Pract; 1999 Aug; 7(8):26-32; quiz 33-4. PubMed ID: 10745719
    [No Abstract]   [Full Text] [Related]  

  • 18. Perspectives in the clinical management of BRCA mutations carriers.
    Savarese A; Cognetti F
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):31-5. PubMed ID: 12585651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproductive issues for women with BRCA mutations.
    Friedman LC; Kramer RM
    J Natl Cancer Inst Monogr; 2005; (34):83-6. PubMed ID: 15784831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hereditary breast cancer.
    Robson ME; Boyd J; Borgen PI; Cody HS
    Curr Probl Surg; 2001 Jun; 38(6):387-480. PubMed ID: 11375625
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.